GSK to market Indian-made anti-tuberculosis drug in Philippines

Published: 5-Dec-2005

The Philippine unit of European drugmaker GlaxoSmithKline (GSK) is to begin locally marketing an Indian manufactured anti-tuberculosis drug next year, according to a statement issued by the company in Manila.


The Philippine unit of European drugmaker GlaxoSmithKline (GSK) is to begin locally marketing an Indian manufactured anti-tuberculosis drug next year, according to a statement issued by the company in Manila.

TB is the sixth leading cause of mortality in the Philippines, with an estimated 27,000 deaths and 19,000 new infections annually.

Following a recent agreement with Mumbai-based Lupin, an Indian leader in anti-tuberculosis product manufacturing, Lupin will supply GSK with anti-TB treatments that comply with WHO specifications. GSK is registering the products with the Bureau of Food and Drugs, and marketing approval is expected in 2006. In October GSK reached agreement with the Aeras Global TB Foundation to develop a vaccine against TB which, if successful would be a big step to control TB in the country.

You may also like